Abstract
Metabolic syndrome (MetS) is a world-wide epidemic disease associated with increased morbidity and mortality. Treatment strategies include pharmacologic and non-pharmacologic methods, with varying degrees of success rate all over the world. Pharmaceutical interest in this field is growing, together with patients’ requests for supplementary (or “alternative”) treatments. The knowledge of nutraceuticals beneficial effects in subjects with the MetS could help us to better define the appropriate treatment for these subjects, in particular those with contraindications for commonly used drugs, or to achieve guidelines suggested targets. On the other side, it could be not convenient to use a nutraceutical to treat each metabolic syndrome component (i.e. from 3 to 5) in each affected subjects. Thus, this review tries to focus on widely marketed nutraceuticals with clinically demonstrated effects on more than one component of the MetS, namely omega-3 fatty acids, berberine, psyllium and other soluble fibers, cinnamon, chromium picolinate, banaba, and bitter gourd.
Keywords: Metabolic syndrome, diabetes, hypertension, dyslipidemia, nutraceuticals, insulin resistance, obesity.
Current Vascular Pharmacology
Title:Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Volume: 12 Issue: 4
Author(s): Arrigo F. Cicero, Elisa Tartagni and Sibel Ertek
Affiliation:
Keywords: Metabolic syndrome, diabetes, hypertension, dyslipidemia, nutraceuticals, insulin resistance, obesity.
Abstract: Metabolic syndrome (MetS) is a world-wide epidemic disease associated with increased morbidity and mortality. Treatment strategies include pharmacologic and non-pharmacologic methods, with varying degrees of success rate all over the world. Pharmaceutical interest in this field is growing, together with patients’ requests for supplementary (or “alternative”) treatments. The knowledge of nutraceuticals beneficial effects in subjects with the MetS could help us to better define the appropriate treatment for these subjects, in particular those with contraindications for commonly used drugs, or to achieve guidelines suggested targets. On the other side, it could be not convenient to use a nutraceutical to treat each metabolic syndrome component (i.e. from 3 to 5) in each affected subjects. Thus, this review tries to focus on widely marketed nutraceuticals with clinically demonstrated effects on more than one component of the MetS, namely omega-3 fatty acids, berberine, psyllium and other soluble fibers, cinnamon, chromium picolinate, banaba, and bitter gourd.
Export Options
About this article
Cite this article as:
Cicero F. Arrigo, Tartagni Elisa and Ertek Sibel, Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/15701611113119990120
DOI https://dx.doi.org/10.2174/15701611113119990120 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Myostatin Inhibition and Cardiometabolic Disorders
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Development of New Fibrinolytic Agents
Current Pharmaceutical Design The Role of Streptokinase as a Virulence Determinant of Streptococcus pyogenes – Potential for Therapeutic Targeting
Current Drug Targets Interactive Effect of Combined Exposure to Active and Passive Smoking on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
Current Pharmaceutical Design Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Recent Developments in PET Instrumentation
Current Pharmaceutical Biotechnology Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry The Role of Dairy Products in Healthy Weight and Body Composition in Children and Adolescents
Current Nutrition & Food Science The Role of Mineral Deficiencies in Insulin Resistance and Obesity
Current Diabetes Reviews Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Editorial (Thematic Issue: Frontiers in Atherosclerosis, Heart Disease and Diabetes)
Cardiovascular & Hematological Disorders-Drug Targets The Effect of Ethyl Acetate Extract of Pomelo Mix on Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design The New Adipose Tissue and Adipocytokines
Current Diabetes Reviews Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology